Beam's Base-Edited Sickle Cell Therapy Hits Its Pivotal Goal, Setting Up the First Base-Editing BLA
On November 10, 2026, Beam Therapeutics announced that risto-cel (ristoglogene autogetemcel), its base-edited cell therapy for sickle cell disease, met the primary endpoint of its pivotal BEACON trial. Beam plans to submit a Biologics License Application (BLA) to the FDA as early as the end of 2026. That would be the first approval request ever filed for a base-editing therapy.
Risto-cel, formerly called BEAM-101, is a one-time treatment made from a patient's own blood stem cells. If approved, it would join Casgevy (the CRISPR-edited therapy from Vertex and CRISPR Therapeutics) and Lyfgenia (bluebird bio) as a gene-based option for people with severe sickle cell disease.
What Beam announced
BEACON is an open-label, single-arm Phase 1/2 trial in adults and adolescents with sickle cell disease who have frequent severe vaso-occlusive crises (VOCs). VOCs are the painful episodes that happen when sickled red blood cells block small blood vessels, and they are the leading reason people with sickle cell disease end up in the hospital.
Primary endpoint met: freedom from severe VOCs for at least 12 consecutive months (called VF12), based on independently adjudicated results at a prespecified interim analysis.
All secondary endpoints met, including 12 consecutive months without a hospital stay for a severe VOC.
All primary safety endpoints met.
Patients: as of the October 20, 2026 data cutoff, 49 people had been treated (39 adults and 10 adolescents). Of these, 31 had been followed long enough to count toward the VF12 endpoint.
Beam CEO John Evans called the result "a defining milestone for risto-cel and for Beam's base editing technology."
The topline announcement did not include percentages, fetal hemoglobin levels, or counts of side effects. Beam says detailed pivotal results will be presented at a medical meeting in 2027.
How risto-cel works
Sickle cell disease is caused by a single mutation in the beta-globin gene (HBB). The mutation makes hemoglobin molecules stick together and bend red blood cells into a rigid sickle shape. Before birth, however, red blood cells use a different form of hemoglobin, fetal hemoglobin (HbF), which does not sickle. After birth, a repressor protein called BCL11A gradually switches fetal hemoglobin off.
Risto-cel switches it back on. Doctors collect the patient's blood stem cells (CD34+ cells), and in the lab a base editor changes single DNA letters in the promoter regions of the two fetal hemoglobin genes, HBG1 and HBG2. The edit is designed to stop BCL11A from binding there, without disrupting BCL11A itself. After chemotherapy conditioning with busulfan clears space in the bone marrow, the edited cells are returned to the patient in a stem cell transplant.
Unlike standard CRISPR-Cas9, which cuts both strands of the DNA double helix, a base editor chemically converts one DNA letter into another without making a double-strand break.
The edit copies a natural condition called hereditary persistence of fetal hemoglobin (HPFH). People who inherit HPFH variants keep making fetal hemoglobin into adulthood, and when they also carry sickle cell mutations, their disease is usually much milder. Natural protective variants like these, and how scientists turn them into medicines, are the focus of my book The Cheat Codes of Our Genes.
What earlier data showed
In April 2026, the New England Journal of Medicine published BEACON results from 31 patients (data cutoff August 6, 2025). Average fetal hemoglobin rose above 60%, and average sickle hemoglobin (HbS) fell below 40%. Anemia resolved in every patient, and no patient had an investigator-reported severe VOC after the edited cells engrafted. The safety profile was consistent with busulfan conditioning, stem cell transplantation, and underlying sickle cell disease.
Those numbers come from an earlier and smaller dataset than the pivotal interim analysis announced this week.
Why it matters
For base editing: Base editing was first described in 2016. Several base editors are now in clinical trials, but none has yet been submitted for FDA approval. A BLA for risto-cel would be the technology's first real test as a marketed medicine.
For patients: Casgevy and Lyfgenia were approved for sickle cell disease in December 2023, so risto-cel would enter a field with established competitors. Beam's chief medical officer, Amy Simon, M.D., has estimated that about 10,000 people with sickle cell disease in the U.S. are eligible for gene therapies. More options could mean more treatment centers and shorter waits.
The limitation: Like the approved therapies, risto-cel still requires stem cell collection and high-dose busulfan conditioning, a chemotherapy that carries serious risks, including infertility and infections. The editing is new; the transplant process is not.
What happens next
December 12, 2026: Ashish Gupta, M.D., MPH, of the University of Minnesota will present BEACON data from an earlier cutoff in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in New Orleans, including the first patient-reported outcomes.
As early as year-end 2026: Beam plans to submit the BLA to the FDA. Risto-cel already holds orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designations.
2027: full pivotal results at a medical meeting.
The bottom line
Risto-cel is now the most advanced base-editing therapy in the world, and its pivotal trial met the goal that matters most to patients: a year or more without severe pain crises. The full numbers at ASH and in 2027, and how the FDA weighs them, will decide its future. But base editing is about to make its first case for approval.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times
Comments